These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 3694926)

  • 1. A case of hyperbilirubinemia during treatment with chenodeoxycholic acid.
    Nakashima T; Sano A; Seto Y; Nakajima T; Okuno T; Takino T
    Jpn J Med; 1987 Aug; 26(3):404-8. PubMed ID: 3694926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver structure and function in cholelithiasis: effect of chenodeoxycholic acid.
    Bell GD; Mok HY; Thwe M; Murphy GM; Henry K; Dowling RH
    Gut; 1974 Mar; 15(3):165-72. PubMed ID: 4152191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lack of relationship between hepatotoxicity and lithocholic-acid sulfation in biliary bile acids during chenodiol therapy in the National Cooperative Gallstone Study.
    Fisher RL; Hofmann AF; Converse JL; Rossi SS; Lan SP
    Hepatology; 1991 Sep; 14(3):454-63. PubMed ID: 1874490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Speed of change in biliary lipids and bile acids with chenodeoxycholic acid--is intermittent therapy feasible?
    Iser JH; Murphy GM; Dowling RH
    Gut; 1977 Jan; 18(1):7-15. PubMed ID: 838406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic morphology and bile acid composition of bile and urine during chenodeoxycholic acid therapy for radiolucent gallstones.
    Pedersen L; Bremmelgaard A
    Scand J Gastroenterol; 1976; 11(4):385-9. PubMed ID: 935799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combination of chenodeoxycholic acid and ursodeoxycholic acid is more effective than either alone in reducing biliary cholesterol saturation.
    Podda M; Zuin M; Dioguardi ML; Festorazzi S; Dioguardi N
    Hepatology; 1982; 2(3):334-9. PubMed ID: 7076116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chenodeoxycholic acid: a review of its pharmacological properties and therapeutic use.
    Iser JH; Sali A
    Drugs; 1981 Feb; 21(2):90-119. PubMed ID: 7009140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids.
    Attili AF; Angelico M; Cantafora A; Alvaro D; Capocaccia L
    Med Hypotheses; 1986 Jan; 19(1):57-69. PubMed ID: 2871479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unconjugated hyperbilirubinemia during treatment with chenodeoxycholic acid.
    Capron JP; Dupas JL; Capron-Chivrac D; Aubin JP; Delamarre J
    Gastroenterology; 1979 Jul; 77(1):121-2. PubMed ID: 447008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal bile acid loss and bile acid pool size during short-term treatment with ursodeoxycholic and chenodeoxycholic acid in patients with radiolucent gallstones.
    Salvioli G; Salati R
    Gut; 1979 Aug; 20(8):698-704. PubMed ID: 488763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of chenodeoxycholic acid (CDCA) on cholesterol absorption.
    Ponz de Leon M; Carulli N; Loria P; Iori R; Zironi F
    Gastroenterology; 1979 Aug; 77(2):223-30. PubMed ID: 447035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics and pool size of chenodeoxycholic acid in cholesterol gallstone patients.
    Pedersen L; Arnfred T
    Scand J Gastroenterol; 1975; 10(5):557-60. PubMed ID: 1153952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometry identification of biliary bile acids in bile from patients with gallstones before and during treatment with chenodeoxycholic acid. An ancillary study of the National Cooperative Gallstone Study.
    Stellaard F; Klein PD; Hofmann AF; Lachin JM
    J Lab Clin Med; 1985 Apr; 105(4):504-13. PubMed ID: 3981060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy for gallstones.
    Schoenfield LJ
    Gastroenterology; 1974 Oct; 67(4):725-9. PubMed ID: 4606798
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of chenodeoxycholic acid feeding during gestation in the rat on bile acid metabolism and liver morphology.
    Sprinkle DJ; Hassan AS; Subbiah MT
    Proc Soc Exp Biol Med; 1984 Mar; 175(3):386-97. PubMed ID: 6694986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes of bile acid and lipid composition in blood and bile in the clinical course after the initiation of cheno- and ursodeoxycholic acid therapy in patients with cholesterol gallstones.
    Iwamura K
    Tokai J Exp Clin Med; 1982 Nov; 7(6):671-83. PubMed ID: 7184199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of response to chenodeoxycholic acid in obese and non-obese patients. Role of cholesterol synthesis and possible response to ursodeoxycholic acid.
    Maton PN; Murphy GM; Dowling RH
    Gut; 1980 Dec; 21(12):1082-6. PubMed ID: 7461467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased sulfation of lithocholate in patients with cholesterol gallstones during chenodeoxycholate treatment.
    Stiehl A; Raedsch R; Kommerell B
    Digestion; 1975; 12(2):105-10. PubMed ID: 1158064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical studies on cheno- and ursodeoxycholic acid treatment for gallstone dissolution.
    Iwamura K
    Hepatogastroenterology; 1980 Feb; 27(1):26-34. PubMed ID: 7203354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy and side effects of ursodeoxycholic and chenodeoxycholic acids in dissolving gallstones. A double-blind controlled study.
    Fromm H; Roat JW; Gonzalez V; Sarva RP; Farivar S
    Gastroenterology; 1983 Dec; 85(6):1257-64. PubMed ID: 6354826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.